For the Quarter Ending December 2025
North America
• In the USA, the Levofloxacin Hemihydrate Price Index fell by 2.68% quarter-over-quarter, driven by feedstock declines.
• The average Levofloxacin Hemihydrate price for the quarter was approximately USD 33361.67/MT, CFR Los Angeles.
• Levofloxacin Hemihydrate Spot Price softened as lower chloroform and isopropyl alcohol costs reduced landed costs.
• Levofloxacin Hemihydrate Price Forecast indicates mild 2026 recovery driven by seasonal purchasing and exporter offers.
• Levofloxacin Hemihydrate Production Cost Trend improved; chloroform and phenol input prices eased, supporting lower offers.
• Levofloxacin Hemihydrate Demand Outlook remains stable with routine hospital purchasing and no significant stockpiling observed.
• Distributor inventories remained comfortable, keeping the Levofloxacin Hemihydrate Price Index subdued despite steady offtake levels.
• Aggressive Indian export offers pressured US CFR values while stable freight avoided logistical cost premia.
Why did the price of Levofloxacin Hemihydrate change in December 2025 in North America?
• Softer chloroform and isopropyl alcohol costs cut Indian exporters' production expenses, prompting year-end competitive discounts.
• Stable trans-Pacific freight and port operations prevented logistical premiums, keeping US landed costs low overall.
• Routine US hospital procurement maintained baseline offtake, avoiding any acute demand-driven substantive price support.
APAC
• In China, the Levofloxacin Hemihydrate Price Index fell by 2.63% quarter-over-quarter, reflecting ample exportable supply.
• The average Levofloxacin Hemihydrate price for the quarter was approximately USD 33276.67/MT FOB Shanghai reported.
• Feedstock easing reduced synthesis costs, pressuring Levofloxacin Hemihydrate Spot Price despite operating rates in clusters.
• Levofloxacin Hemihydrate Price Forecast points to monthly fluctuations driven by seasonal procurement and inventory adjustments.
• Chloroform and phenol easing supported a Levofloxacin Hemihydrate Production Cost Trend, enabling competitive export offers.
• Levofloxacin Hemihydrate Demand Outlook remained muted as VBP awards capped domestic restocking and international destocking.
• Rising exportable volumes and balanced inventories pressured offers; the Levofloxacin Hemihydrate Price Index trended downward.
• Coastal plants ran near capacity without major outages, sustaining supply and maintaining shipping schedules reliably.
Why did the price of Levofloxacin Hemihydrate change in December 2025 in APAC?
• Expanded export-available output outpaced muted domestic and international offtake, exerting downward pressure on December pricing.
• Slightly firmer fluoro-benzene and chloroform marginally raised cash costs but failed to offset inventory growth.
• Normalized Shanghai port operations reduced freight risk, enabling exporters to consistently sustain competitive FOB offers.
Europe
• In Germany, the Levofloxacin Hemihydrate Price Index fell by 2.72% quarter-over-quarter, reflecting feedstock relief and increased imports.
• The average Levofloxacin Hemihydrate price for the quarter was approximately USD 33360.00/MT, reflecting subdued spot activity.
• Levofloxacin Hemihydrate Spot Price softened amid eased chloroform costs and stable Hamburg logistics supporting lower delivered offers.
• Levofloxacin Hemihydrate Price Forecast expects mild recovery as year-end restocking and stable upstream operations gradually tighten availability.
• Levofloxacin Hemihydrate Production Cost Trend improved due to lower chloroform and phenol prices, reducing origin API manufacturing expenses.
• Levofloxacin Hemihydrate Demand Outlook remains steady with routine hospital procurement and limited substitution, supporting balanced market dynamics.
• Levofloxacin Hemihydrate Price Index movement influenced by comfortable inventories, normal Rhine shipping, and competitive Asian export quotes.
• Export demand and port efficiencies constrained volatility, keeping the Levofloxacin Hemihydrate Price Index broadly neutral through the seasonal transition.
Why did the price of Levofloxacin Hemihydrate change in December 2025 in Europe?
• Lower chloroform and phenol costs in Asia reduced API production costs and pressured CIF offers into Germany.
• Improved Hamburg port operations and Rhine inland logistics accelerated deliveries, supporting ample imports and comfortable distributor inventories.
• Cautious buyer restocking and fixed health-insurer reference pricing limited upside, keeping spot purchasing subdued and prices softer.
For the Quarter Ending September 2025
North America
• In USA, the Levofloxacin Hemihydrate Price Index fell by 4.6% quarter-over-quarter, reflecting destocking and weaker bookings.
• The average Levofloxacin Hemihydrate price for the quarter was approximately USD 34280/MT, CFR Los Angeles reported.
• Levofloxacin Hemihydrate Spot Price softened as inventory overhang and freight corrections reduced immediate buyer urgency nationwide.
• Levofloxacin Hemihydrate Price Forecast anticipates mild sequential gains driven by selective restocking and holiday-season procurement activity.
• Levofloxacin Hemihydrate Production Cost Trend eased as handling and freight corrections reduced supplier margin pressures materially.
• Levofloxacin Hemihydrate Demand Outlook improved in August as Golden Week restocking prompted higher import volumes broadly.
• Levofloxacin Hemihydrate Price Index volatility reflected tariff uncertainty, port delays, and strategic stockpiling affecting short-term balances.
• Levofloxacin Hemihydrate Spot Price and Price Index remain rangebound as inventories normalize and buying becomes selective.
Why did the price of Levofloxacin Hemihydrate change in September 2025 in North America?
• Earlier Q2 stockpiles and subdued summer bookings led to destocking and downward price pressure in September.
• Port congestion and logistics corrections temporarily tightened supply, prompting targeted purchases and supporting modest price recovery.
• Tariff uncertainty and cautious procurement restrained large contracts, keeping transactional volumes subdued despite selective restocking ahead.
APAC
• In China, the Levofloxacin Hemihydrate Price Index fell by 4.52% quarter-over-quarter, driven by weak exports.
• The average Levofloxacin Hemihydrate price for the quarter was approximately USD 34176.67/MT FOB Shanghai shipments.
• Levofloxacin Hemihydrate Spot Price weakened as suppliers offered discounts to clear domestic and international inventories.
• Levofloxacin Hemihydrate Price Forecast indicates modest recovery as buyers replenish stocks ahead of Q4 restocking.
• Levofloxacin Hemihydrate Production Cost Trend softened with lower logistics and input prices, reducing pricing power.
• Levofloxacin Hemihydrate Demand Outlook remains cautious due to adequate inventories abroad and subdued domestic buying.
• Levofloxacin Hemihydrate Price Index volatility reflected shipping disruptions, tariff-driven demand surges, and export competition effects.
• Producers adjusted production schedules and spot volumes to manage stock builds and sustain export presence.
Why did the price of Levofloxacin Hemihydrate change in September 2025 in APAC?
• Export demand normalization reduced order flow, leaving excess stocks and pressuring spot prices and FOB offers.
• Falling freight and input costs lowered export breakevens, enabling sellers to reduce prices to stimulate offtake.
• Buyers delayed purchases anticipating stabilization, reducing near-term demand despite some restocking ahead of year-end holidays.
Europe
• In Germany, the Levofloxacin Hemihydrate Price Index fell by 4.44% quarter-over-quarter, reflecting inventory liquidation and procurement activity.
• The average Levofloxacin Hemihydrate price for the quarter was approximately USD 34291.67/MT reported by exporters.
• Levofloxacin Hemihydrate Spot Price weakened as elevated inventories and delayed PSS implementations reduced buying urgency.
• Levofloxacin Hemihydrate Price Forecast indicates recovery driven by restocking ahead of Golden Week and seasonal demand.
• Levofloxacin Hemihydrate Production Cost Trend shows upward pressure from postponed PSS and elevated freight premiums.
• Levofloxacin Hemihydrate Demand Outlook remains cautious with restocking by hospitals and wholesalers into late quarter.
• Levofloxacin Hemihydrate Price Index recovered in August as export availability tightened and importers accelerated orders.
• Producers' maintenance outages in China reduced immediate shipments, supporting spot tightness and pressuring distributor margins.
Why did the price of Levofloxacin Hemihydrate change in September 2025 in Europe?
• Elevated inventories led buyers to delay purchases, reducing spot demand and softening net price movement.
• Postponed Peak Season Surcharges kept immediate freight costs muted, limiting short-term landed cost increases materially.
• Port congestion and security risks prompted cautious procurement, while some Chinese maintenance reduced export offers.
For the Quarter Ending June 2025
North America
• The Levofloxacin Hemihydrate Spot Price in Los Angeles saw mixed movements in Q2 2025 with a Price Index rising 5.11% in April, 7.79% in May, then declining by 8.52% in June, reflecting shifting supply and demand dynamics.
• April’s Price Index increase was driven by frontloading ahead of a 145% U.S. tariff on Chinese imports, causing supply chain pressures and elevated landed costs. Market participants intensified procurement, pushing prices upward amid steady demand supported by a slowdown in U.S. inflation.
• In May, the Price Index rose sharply due to a 90-day tariff suspension prompting accelerated import activity and logistical bottlenecks at ports like Los Angeles, further increasing landed costs and freight surcharges. Procurement surged as buyers sought to mitigate post-August tariff risks.
• June’s Price Index declined as strategic stockpiling earlier in the quarter reduced immediate buying needs. Ocean freight costs corrected downward, inventory destocking increased, and weaker consumer confidence dampened demand.
• The Levofloxacin Hemihydrate Price Forecast for July 2025 anticipates a modest increase as suppliers cautiously restock, creating localized supply tightness.
• The Product Production Cost Trend in Q2 was influenced by tariff-induced freight surcharges and supply chain congestion, adding cost pressures in April and May, easing in June.
• The Product Demand Outlook reflects cautious buyer behavior moving into Q3, with distributors shifting from discount-driven liquidation to margin restoration, supporting slight upward price momentum.
• Overall, the USA Levofloxacin Hemihydrate market experienced volatile Price Index fluctuations driven by tariff policy shifts, procurement frontloading, and macroeconomic factors affecting demand and supply throughout Q2.
APAC
• The Levofloxacin Hemihydrate Price Index in China rose sharply in April 2025 due to sustained procurement and supply tightness, with the Product Spot Price increasing by 5.19%.
• Strong domestic demand and strategic stockpiling by pharmaceutical manufacturers, combined with U.S. importers accelerating orders ahead of 145% tariffs, underpinned April’s firm Product Demand Outlook.
• Manufacturing faced a slowdown as China’s PMI contracted, but supply remained constrained, supporting upward price momentum despite logistical pressures.
• In May, the Price Index further increased by 7.75%, driven by strong international demand and freight capacity tightening linked to a temporary 90-day tariff pause.
• Exporters faced surging container rates and vessel space constraints, pushing up Product Production Cost Trends and enabling suppliers to raise prices amid peak season shipping demand.
• U.S. and other global buyers frontloaded inventories in May, amplifying export volumes and maintaining robust Product Demand Outlook despite logistical bottlenecks.
• June saw an 8.73% decline in the Price Index, as export demand weakened, excess inventories built up, and global freight costs fell sharply, easing supply pressures.
• Domestic pharmaceutical consumption slowed, and buyers delayed purchases anticipating further price drops, softening the Product Spot Price.
• The broader economic environment, including a 3.6% decline in China’s Producer Price Index, pressured export pricing power and contributed to June’s price correction.
• For July 2025, a short-term buying revival is expected as some international players seek to replenish stocks after June’s dip, but inventory pressure and cautious production schedules may limit significant price rises.
Europe
• The Levofloxacin Hemihydrate Spot Price in Germany increased in April 2025, with the Price Index rising by 5.14%, driven by seasonal logistics disruptions, port congestion, and rerouted shipments due to U.S. tariffs on Chinese pharmaceutical imports.
• April's tighter supply was compounded by holiday-related delivery delays across key Northern European ports (Hamburg, Antwerp, Rotterdam), causing cautious supplier inventory strategies and firm pricing.
• Consumer confidence improved modestly as Germany’s inflation eased (CPI at 2.1%), boosting pharmaceutical demand and supporting the upward price momentum.
• In May, the Price Index surged 7.71%, reflecting escalating port congestion, vessel space shortages, industrial actions, and low Rhine water levels impacting barge traffic.
• Shipping lines introduced congestion surcharges and space controls, while strategic shifts in global shipping routes reduced Asia-Europe vessel availability, tightening supply to Germany.
• Heightened procurement ahead of June's anticipated General Rate Increase (GRI) intensified competition, pushing spot prices higher.
• June saw an 8.63% decline in the Price Index as inventories accumulated, procurement slowed, and participants focused on stock clearance amid postponed Peak Season Surcharges (PSS).
• Despite ongoing port bottlenecks, deferred freight cost increases eased immediate landed cost pressures, weakening price trends.
• The Levofloxacin Hemihydrate Demand Outlook for July 2025 anticipates moderate demand recovery as downstream industries refill pipelines after Q2 inventory drawdowns.
• However, activation of postponed PSS in July is expected to raise freight costs, slightly increasing landed import prices and potentially driving a modest upward adjustment in the Product Price Forecast.
For the Quarter Ending March 2025
North America
In Q1 2025, Levofloxacin Hemihydrate prices in the USA experienced moderate fluctuations. January saw a price increase due to stockpiling in anticipation of a 10% tariff on Chinese goods set to take effect in February and the Chinese Lunar New Year, which boosted demand. Additionally, rising energy costs and port congestion, worsened by California wildfires, strained supply chains and contributed to higher prices.
In February, prices declined as supply improved, driven by post-Lunar New Year manufacturing increases in China and reduced shipping costs. However, weak demand—due to economic uncertainty, rising inflation, and cautious buying amid tariff concerns—put downward pressure on prices. Many buyers had stocked up in January and February to mitigate future tariff-related costs, reducing the need for immediate replenishment.
March saw a slight price rebound as businesses rushed to secure inventory ahead of potential further tariffs, with trade disruptions adding volatility to supply chains. Easing inflation slightly improved consumer sentiment, supporting firm prices despite ongoing uncertainty. Geopolitical factors and tariff-related purchasing behavior were central to Q1's price trends.
Asia Pacific
In the first quarter of 2025, Levofloxacin Hemihydrate prices in China exhibited notable fluctuations driven by supply-demand dynamics. January saw a slight price increase due to strong demand from the pharmaceutical and healthcare sectors, combined with reduced manufacturing output before the Lunar New Year. Anticipating supply shortages, manufacturers and distributors placed advance orders, and export frontloading, driven by fears of U.S. tariffs, added pressure. However, February witnessed a slight price decline, as stable supply and weak demand balanced the market. The post-holiday period saw an uptick in manufacturing, but reduced export competitiveness and weak domestic consumption led to higher inventories and softer demand. By March, prices increased again as supply struggled to meet heightened demand. Although manufacturing activity improved, low inventory levels and increased procurement—partly driven by foreign buyers and fiscal stimulus—tightened the market, leading to higher prices. This combination of factors—seasonal effects, U.S. tariffs, and fluctuating demand—shaped the Levofloxacin Hemihydrate market in China during Q1 2025.
Europe
In Q1 2025, Levofloxacin Hemihydrate prices in Germany showed a mixed trend. January experienced a moderate price increase, driven by improved business sentiment and stronger demand from the healthcare and pharmaceutical sectors. Optimism in the economic climate, supported by looser monetary policy, led to increased orders, while inventory restocking ahead of the Lunar New Year placed additional pressure on prices. In February, prices declined as supply conditions remained ample and demand weakened. Favorable import conditions, including a stronger Euro and lower ocean freight rates, allowed for cost-effective imports, while early stockpiling left the market oversupplied. Weak consumer sentiment amid political uncertainty led to cautious spending, prompting suppliers to reduce prices to stay competitive. By March, prices rebounded due to tightening supply, caused by port congestion and labor unrest across Europe. At the same time, restocking activity resumed, and improved sentiment in the pharmaceutical sector contributed to stronger demand. With these factors, suppliers increased prices, resulting in a recovery from February’s dip. Overall, Q1 2025 saw initial price increases, followed by a decline, and a March recovery.
